HTS Classification by industry
Pharmaceutical imports involve active pharmaceutical ingredients (APIs), finished dosage forms, biologics, and medical devices — each with distinct classification rules under Chapters 29, 30, and 90. The difference between a bulk chemical and a pharmaceutical preparation can mean 0% versus 6.5% duty. Camtom navigates INN names, dosage forms, and FDA regulatory classifications to find the optimal HTS code.
Distinguishing between bulk APIs (Ch. 29) and dosage-form preparations (Ch. 30) when the product is partially formulated
Classifying combination drugs that contain multiple active ingredients under the correct subheading
Navigating the pharmaceutical appendix (HTS General Note 13) for duty-free eligibility on INN-listed compounds
Determining whether diagnostic kits classify as reagents (3822) or instruments (9027)
Handling biologics and biosimilars that do not fit neatly into traditional chemical classification categories
Classifying a finished tablet under Chapter 29 (organic chemicals) instead of 3004 (medicaments in measured doses)
Missing duty-free treatment for INN-listed APIs that qualify under the pharmaceutical appendix
Classifying veterinary pharmaceuticals under human pharma subheadings — Chapter 30 separates these
Treating a medical device accessory as a pharma product when it should go under Chapter 90
Failing to declare the dosage form (capsule, injectable, topical) which drives the 6-digit classification
Many APIs enter duty-free under the Pharmaceutical Appendix (General Note 13). Finished dosage forms under 3004 face 0% to 6.5% depending on formulation. Medical devices under Chapter 90 range from 0% to 2.5%.
Under USMCA, pharmaceutical products qualify for preferential treatment when they undergo a tariff shift from Chapter 29 (API) to Chapter 30 (finished drug) within a USMCA country. Biologics produced in USMCA countries generally qualify. Certificate of origin or importer certification is required.